|[January 17, 2013]
Research and Markets: Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/wpfnbh/afluria_seasonal)
has announced the addition of GlobalData's new report "Afluria (Seasonal
Influenza Vaccines) Forecast and Market Analysis" to their offering.
GlobalData has released its new PharmaPoint Drug Evaluation report,
Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis.
Seasonal Influenza is a respiratory infection caused by influenza virus
that results in mild to severe symptoms, such as fever, cold and cough.
The market is heavily driven by the sales of prophylactic vaccine
treatments to prevent infection. Currently, trivalent intramuscular
vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's
Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of
the market. However, with the entrance of vaccines with novel routes of
administration, such as AstraZeneca's intranasal FluMist and Sanofi's
Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the
adoption of such vacines over the traditional intramuscular vaccines.
GlobalData also anticipates that manufacturers that launch quadrivalent
formulations will steal market share, patient share, and revenue from
the trivalent influenza vaccines currently available.
Afluria is a trivalent, inactivated vaccine designed to immunize
recipients against seasonal influenza A and B viruses. Afluria is
manufactured from viruses that were grown in chicken eggs, harvested via
centrifugation, inactivated with beta-propiolactone, disrupted (i.e.,
split) with a detergent, prior to purification and suspension in a
saline buffer. The vaccine is administered via intramuscular injection,
where the viral antigens elicit an immune response that helps protect
the recipient against seasonal influenza infection. An increased
incidence of febrile seizures in patients less than nine years old was
associated with the 2010-2011 formulation, which prompted governing
panels to recommend against administering Afluria to young children.
Afluria is manufactured by CSL Biotherapies, which has marketing
agreements with Merck and Pfizer to distribute the vaccine in the US and
- Overview of seasonal influenza, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Detailed information on Afluria including product description, safety
and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Afluria for the top nine countries from 2012 to
- Sales information covered for the US, France, Germany, the UK, Italy,
Spain, Japan, China and India
Key Topics Covered:
1 List of Tables and Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
For more information visit http://www.researchandmarkets.com/research/wpfnbh/afluria_seasonal
Source (News - Alert): GlobalData
[ InfoTech Spotlight's Homepage ]